[Bisphosphonates in oncology].
Since bone metastases occur as a result of hematogenous spreading of tumor cells, therapy with curative intent is no longer feasible and palliative options for treating and preventing skeletal events are essential. Today, bisphosphonates are established in the systemic treatment of bone metastases. This report provides an overview of molecular mechanisms of action and clinical data of bisphosphonates in patients with skeletal metastases of breast and prostate cancer as the most common solid tumors which spread to the bone.
Kurth
A A
AA
Orthopädische Universitätsklinik, Stiftung Friedrichsheim, Marienburgstrasse 2, 60528 Frankfurt/M. A.Kurth@friedrichsheim.de
Heidenreich
A
A
Diel
I
I
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000523:psychology / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control* / Q000523:psychology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011788:Quality of Life / Q000523:psychology; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D004164:Diphosphonates